Flamingo AI updates the market on business developments

|

Published 11-OCT-2018 11:33 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Flamingo AI Limited (ASX:FGO) has today provided the market with a business update. As reported by the company in July, FGO had 10 clients progressing through various stages of trial, deployment, live customer evaluation and post-trial assessment of the Flamingo AI platform.

The intention behind the trials is to determine the best application of FGO’s various cognitive technologies within the client’s business, which may not necessarily be the initial trial Use Case.

FGO’s update focused in particular on two of its clients, AMP and Liberty Mutual Insurance, reporting that AMP has undertaken a paid Proof of Concept trial of one of FGO’s Cognitive Virtual Assistant products on one of its product lines.

At the recent conclusion of the trial, FGO were advised that the trial would not progress to full rollout. However, the company is continuing to engage positively with AMP on other uses of its technology to assist with the operation of their business.

In addition, Liberty Mutual undertook a paid Proof of Technology trial of FGO’s Cognitive Virtual Assistant product in its Auto Insurance line, which also recently finished. While Liberty Mutual has advised it will not continue with this specific Use Case, they have requested further proposals related to FGO’s products across a number of their business lines, including Auto insurance.

FGO is now engaging with Liberty Mutual to develop these proposals and determine the most suitable applications of their Virtual Assistant technology for the insurer.

The small cap’s other clients are at various stages of implementation including live customer evaluation.

Strong interest continues for FGO’s machine learning and virtual assistant tech

FGO continues to generate strong interest in its products and machine learning technology from existing and new clients, with much of the interest focusing on the ROSIE Virtual Sales Assistant product, the MAGGIE Virtual Inquiry Assistant product, and the LIBBY Knowledge Engine or Self-Organising Library product.

FGO also reported that its partnership with EXL Services (NASDAQ:EXLS) — clinched in May this year — remains particularly strong, with FGO engaging in several streams of work. This has included participating in joint pitches where FGO provides the Conversational AI layer to EXL’s robotic automation and data analytics platform.

EXL has also showcased FGO’s technology in dedicated EXL conferences to insurance clients.

Overall this is an early stage play and as such any investment decision should be made with caution and professional financial advice should be sought.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X